Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cygnal Therapeutics

Request full access

Cygnal Therapeutics is a biotechnology company

Cambridge, United StatesFounded 2016Biotech & Life Sciences

About Cygnal Therapeutics

Cygnal Therapeutics, a biopharmaceutical company launched in 2017, was incubated and financed by Flagship Pioneering. The company's scientific foundation is rooted in the emerging field of exoneural biology, which explores the role of peripheral nerves in health and disease. This novel approach targets the nervous system's influence on immunology, inflammation, and metabolic diseases, moving beyond traditional drug development that focuses on single-cell targets.

The company was founded by a team from Flagship Pioneering, including Stéphane Budel, who also served as the founding President and later CEO. Budel brought extensive experience in biopharmaceutical strategy and operations to the venture. The scientific co-founder is Dr. Avram Hershko, a Nobel Laureate in Chemistry, whose work on the ubiquitin system provided foundational insights. This venture originated from an exploration within Flagship Labs, led by a team including Avak Kahvejian and David Berry, to investigate the signaling conversations between nerves and other tissues.

Cygnal's core business revolves around developing a new class of medicines to stimulate nerve-driven repair mechanisms. The company has developed the Exoneural Medicine Platform, a proprietary system designed to understand and modulate the signaling between the peripheral nervous system and non-neural cells. This platform integrates single-cell and neuronal genomics, advanced imaging, and bioinformatics to identify novel drug targets and develop therapeutics. The primary clients for these potential therapies are patients suffering from conditions where nerve activity plays a critical but previously untargeted role, such as cancer and inflammatory diseases. The business model is typical of a preclinical biopharmaceutical firm, focusing on research and development with the goal of advancing drug candidates into clinical trials, potentially leading to partnerships, licensing deals, or eventual commercialization.

In a significant milestone, Cygnal Therapeutics entered into a definitive merger agreement with Cullinan Oncology, Inc. in March 2021. Under the terms of the agreement, Cullinan acquired Cygnal, including its two-asset portfolio and the underlying exoneural biology platform, in an all-stock transaction. This strategic move provided Cygnal's programs with the resources and clinical development expertise of Cullinan to advance its novel drug candidates. Prior to the acquisition, Cygnal operated primarily in a research and development capacity, having not yet brought a product to market.

Source: Dealroom company data

At a glance

Status
Operational
Employees
11
Open positions
None listed
Dealroom signal
60.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Oct 2019 $65M $260M Flagship Pioneering —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Cygnal Therapeutics website traffic

Latest recorded traffic for Cygnal Therapeutics is 200 monthly website visits, up 53.8% over the last three months. Cygnal Therapeutics's team grew 0% over the past year.

Latest monthly visits200 3-month web change+53.8% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cygnal Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Cygnal Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cygnal Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cygnal Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.